Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer

A Argiris, S Li, P Savvides, JP Ohr, J Gilbert… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE We evaluated the addition of bevacizumab, a humanized monoclonal antibody
that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent …
被引用次数：90 相关文章

Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer

A Argiris, S Li, P Savvides, JP Ohr… - Journal of Clinical …, 2019 - pure.johnshopkins.edu
PURPOSE We evaluated the addition of bevacizumab, a humanized monoclonal antibody
that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent …
[PDF] core.ac.uk

[PDF][PDF] Let us know how access to this document benefits yo u

J Gilbert, A Argiris, S Li, P Savvides, JP Ohr, J Gilbert… - core.ac.uk
RESULTS The study randomly assigned 403 patients. Median overall survival (OS) was
12.6 months with bevacizumab plus chemotherapy (BC) and 11.0 months with …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

A Argiris, S Li, P Savvides, JP Ohr… - Journal of clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Purpose We evaluated the addition of bevacizumab, a humanized monoclonal antibody that
targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

A Argiris, S Li, P Savvides, JP Ohr, J Gilbert… - Journal of Clinical …, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> We evaluated the addition of
bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

A Argiris, S Li, P Savvides, JP Ohr, J Gilbert, MA Levine… - 2019 - jdc.jefferson.edu
PURPOSE: We evaluated the addition of bevacizumab, a humanized monoclonal antibody
that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.

A Argiris, S Li, P Savvides, JP Ohr, J Gilbert… - Journal of Clinical …, 2019 - europepmc.org
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With
Recurrent or Metastatic Head and Neck Cancer. - Abstract - Europe PMC Sign in | Create an …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

A Argiris, S Li, P Savvides, JP Ohr… - Journal of clinical …, 2019 - scholarship.miami.edu
Abstract Antineoplastic Agents, Immunological-administration & dosage Antineoplastic
Combined Chemotherapy Protocols-administration & dosage Bevacizumab-administration & …

Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer

A Argiris, S Li, P Savvides, JP Ohr… - Journal of Clinical …, 2019 - ohiostate.elsevierpure.com
PURPOSE We evaluated the addition of bevacizumab, a humanized monoclonal antibody
that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent …

Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

A Argiris, S Li, P Savvides, JP Ohr… - Journal of …, 2019 - scholarlycommons.gbmc.org
Purpose: We evaluated the addition of bevacizumab, a humanized monoclonal antibody that
targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or …